ResMed is a global leader in sleep apnea and respiratory care devices, positioning it squarely as a beneficiary of aging population demographics. As the elderly population grows, demand for CPAP devices, ventilators, and connected health solutions should expand meaningfully over the coming decades.

Financially, ResMed trades at a P/E of 32x with EPS of $7.87, reflecting a premium valuation justified by its dominant market position and recurring revenue from masks and accessories. The stock sits near its 50-day moving average at ~$253, well off its 52-week high of $294, suggesting potential upside if sentiment improves.

Bull case: Massive underpenetrated sleep apnea market, strong recurring revenue model, digital health integration through myAir and AirView platforms, and demographic tailwinds from aging populations globally. Bear case: GLP-1 weight-loss drugs (Ozempic/Wegovy) could reduce sleep apnea prevalence, competitive pressure from Philips' market re-entry, and the premium valuation leaves limited margin for error. The 90-day decline of -10.25% likely reflects lingering GLP-1 concerns. Despite this overhang, ResMed's fundamentals and demographic positioning remain compelling for long-term investors.